Vyskocil E, et al. - Researchers performed a prospective cohort study to assess if β-catenin, TCF21 and WISP1 expression have value for prognosis in patients with squamous cell carcinomas of the head and neck who underwent primary radiotherapy or concomitant chemoradiotherapy. Via immunohistochemical analyses, they assessed protein expression profiles of β-catenin, TCF21, WISP1 and p16 in tissue samples of 59 untreated patients. Outcomes suggest the prognostic value of TCF21 for disease-specific survival and of WISP1 and ß-catenin for clinical outcome after definitive radiotherapy. Significantly worse disease-specific survival was linked to patients with high expression of TCF21. TCF21 was a significant factor for disease-specific survival in a multivariable analysis, while a better response to radiotherapy was linked to low expression of β-catenin and WISP1.